

# Lupus: Open Access

**Editorial Note** 

## Study to Create Awareness on Lupus Discod

## Yues Renaudineau\*

Immunotherapy Graft Oncology, Innovative Medicines initiative precisesads, Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France

#### **EDITORIAL NOTE**

Lupus is a incurable autoimmune disease which attacks the body's normal and healthy tissues becoming hyperactive. It shows symptoms including swelling, inflammation, rashes(Malar, Discoid or photosensitive), damage to the joints, blood, kidney(Lupus Nephrites), skin(Subcutaneous/cutaneous Lupus), heart, brain(Cerebral/CNS Lupus) and lungs also , Musculoskeletal Problems, Anemia, Seziures, Serositis and several many more. People sometimes call lupus the "disease of 1,000 faces" due to its complex nature. Lupus may develop in response to a number of factors including hormonal, environmental, genetic or a combination of these.

Lupus: Open Access is only fully peer reviewed International Scholarly journal devoted exclusively to disseminate on going lupus research throughout the world with latest advancements in all fields of Lupus and Related auto immune disorders.

We take extreme pleasure in upholding this prestigious journal which has a prominent history of successful running for past 04 years. We are very grateful and appreciative for our outstanding team of Authors, Reviewers and honorable Editorial board members who has played major role in success of this reputable journal. We believe that this would be another fantastic year in publishing quality research outcomes which has diversified platforms for accessing all the articles through Social media like Twitter, Linked In, Facebook, What's app etc., articles can be viewed at a single click!!

The 05th volume of the esteemed journal addresses the novel research performed by authors from different parts of the world. Timlin H in his mini review says about their study in identifying

patients with biopsy clinically proven hydralazine induced lupus nephritis aiming to raise attention for biopsy proven hydralazine-induced nephritis [1].

An article which is well concluded by Yoshiya Tanaka et all on activated B cells, especially P-gp+CD27-IgD- memory B cells and P-gp+CXCR4+CD19+ plasmablasts deciphering that these seem to play important roles in the pathogenesis of TRLV, resulting in the development of treatment resistance and poor renal outcome [2].

This Journal successfully completes 04 years in publication of quality research work globally being an Editorial board member for this prestigious journal I hereby discloses the scientific trends and research updates of our journal.

We sincerely thank our honourable editorial board members, esteemed authors and research personalities who contributed for journal and respected reviewers who supported us in rapid peer review process and all our supporting members who worked rigorously for success and development of this reputable journal. Upon entering into 2020 , Lupus: Open Access anticipates renowned eminent researchers across the globe to share their valuable presentation and galvanize the scientific community in upcoming issues.

### REFERENCES

- 1. Timlin H, Shiroky J, Wu M, Geetha D. Hydralazine Induced Lupus Nephritis. Lupus: Open Access. 2020;5(1):1-2.
- Shizuyo Tsujimura, Akio Kawabe, Yoshiya Tanaka. P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis. Lupus: Open Access. 2020;5(1):1-6.

Received: Nov 10, 2020; Accepted: Nov 17, 2020; Published: Nov 28, 2020

Citation: Renaudinau Y (2020) First Study to Create Awareness on Lupus Lupus: Open Access 5:e108. DOI: 10.35248/2684-1630.20.5.e108.

Copyright: © 2020 Renaudineau Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

<sup>\*</sup>Correspondence to: Yves Renaudineau, Immunotherapy Graft Oncology, Innovative Medicines initiative precisesads, Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France; E-mail: yves.renaudineau@univ-brest.fr